Editorial: Challenges and Conundrums in Cannabinoid-Based Treatments for Epilepsy Syndromes and Associated Neurobehavioral Comorbidities

Front Behav Neurosci. 2021 Nov 11:15:781852. doi: 10.3389/fnbeh.2021.781852. eCollection 2021.

Ricardo Gómez-Nieto^{1

2

3}, Dolores E López^{1

2

3}, Norberto Garcia-Cairasco^{4

5}

¹ Institute of Neuroscience of Castilla y León, University of Salamanca, Salamanca, Spain.
² Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
³ Department of Cell Biology and Pathology, Faculty of Medicine, University of Salamanca, Salamanca, Spain.
⁴ Neurophysiology and Experimental Neuroethology Laboratory, Physiology Department, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil.
⁵ Department of Neuroscience and Behavioral Sciences, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, Brazil.

No abstract available

Keywords: antiseizure medications; cannabidiol; cannabinoids; clinical epilepsy; comorbidities; epilepsy; experimental-animal models; seizure.

Publication types